AstraZeneca: oncology drug approved by the FDA.
(CercleFinance.com) - AstraZeneca said that the US Food and Drug Administration has granted accelerated approval to Calquence for adult patients with mantle cell lymphoma (MCL).
"This first indication is a relatively small one for the drug out of a very large clinical programme but it is good to have the oncology franchise's fourth growth driver now approved," analysts at Bryan Garnier said.
The broker - which has a "buy" rating on the shares - said the clinical results of the drug were "outstanding" in this indication.
This news helps to offset disappoining results in severe asthma, with AstraZeneca saying that a Phase III on human monoclonal antibody tralokinumab trial did not achieve a statistically-significant reduction in oral corticosteroid use, the primary endpoint.
Finally, AstraZeneca has completed a marketing agreement with Aspen, under which the latter has acquired the rights to several anaesthetic medicines in markets outside the US.
Following the news, AstraZeneca shares were up 1.4% at 5,103 pence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"This first indication is a relatively small one for the drug out of a very large clinical programme but it is good to have the oncology franchise's fourth growth driver now approved," analysts at Bryan Garnier said.
The broker - which has a "buy" rating on the shares - said the clinical results of the drug were "outstanding" in this indication.
This news helps to offset disappoining results in severe asthma, with AstraZeneca saying that a Phase III on human monoclonal antibody tralokinumab trial did not achieve a statistically-significant reduction in oral corticosteroid use, the primary endpoint.
Finally, AstraZeneca has completed a marketing agreement with Aspen, under which the latter has acquired the rights to several anaesthetic medicines in markets outside the US.
Following the news, AstraZeneca shares were up 1.4% at 5,103 pence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.